AstraZeneca’s Vaxzevria Demonstrates Effectiveness After One Dose Against Beta/Gamma and Delta Variants of SARS-CoV-2 Virus
AstraZeneca Presents Results of Imfinzi (durvalumab) + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV NSCLC at WCLC 2021
Shots:
- RWE data from CIRN with support from the Public Health Agency of Canada and the Canadian Institutes of Health Research demonstrated that one dose of Vaxzevria was 82% effective against hospitalization or death caused by the Beta/Gamma variants of the SARS-CoV-2 virus
- The vaccine also demonstrated effectiveness against the Delta and Alpha variants with an 87% and 90% reduction of hospitalizations or deaths respectively
- The RWE study includes 69,533 individuals who tested positive for SARS-CoV-2 during Dec’2020 to May’2021 in Canada with 28,705 (6.8%) positive for non-variants of concern SARS-CoV-2 and 40,828 (9.7%) positive for a variant of concern
Click here to read full press release/ article | Ref: AstraZeneca | Image: AstraZeneca